

# Ken A Brameld

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1745715/publications.pdf>

Version: 2024-02-01

21  
papers

1,726  
citations

430874

18  
h-index

713466

21  
g-index

23  
all docs

23  
docs citations

23  
times ranked

2779  
citing authors

#	ARTICLE	IF	CITATIONS
1	Small Molecule Conformational Preferences Derived from Crystal Structure Data. A Medicinal Chemistry Focused Analysis. <i>Journal of Chemical Information and Modeling</i> , 2008, 48, 1-24.	5.4	334
2	Prolonged and tunable residence time using reversible covalent kinase inhibitors. <i>Nature Chemical Biology</i> , 2015, 11, 525-531.	8.0	324
3	The p <i>K</i> <sub>BHX</sub> Database: Toward a Better Understanding of Hydrogen-Bond Basicity for Medicinal Chemists. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 4073-4086.	6.4	276
4	Substrate assistance in the mechanism of family 18 chitinases: theoretical studies of potential intermediates and inhibitors 1 Edited by B. Honig. <i>Journal of Molecular Biology</i> , 1998, 280, 913-923.	4.2	110
5	Distance Dependent Hydrogen Bond Potentials for Nucleic Acid Base Pairs from ab Initio Quantum Mechanical Calculations (LMP2/cc-pVTZ). <i>Journal of Physical Chemistry B</i> , 1997, 101, 4851-4859.	2.6	97
6	Substrate Distortion to a Boat Conformation at Subsite 1 Is Critical in the Mechanism of Family 18 Chitinases. <i>Journal of the American Chemical Society</i> , 1998, 120, 3571-3580.	13.7	93
7	Discovery of the Irreversible Covalent EGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3- <i>d</i> ]pyrimidin-7(8 <i>H</i> )-one (PRN1371) for the Treatment of Solid Tumors. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 6516-6527.	8.3	83
8	Ab Initio Quantum Mechanical Study of the Structures and Energies for the Pseudorotation of 5'-Dehydroxy Analogues of 2'-Deoxyribose and Ribose Sugars. <i>Journal of the American Chemical Society</i> , 1999, 121, 985-993.	13.7	78
9	Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated Disease. <i>Journal of Immunology</i> , 2021, 206, 1454-1468.	0.8	50
10	Quinolones as HCV NS5B polymerase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 82-87.	2.2	39
11	Targeting Interleukin-2-inducible T-cell Kinase (ITK) and Resting Lymphocyte Kinase (RLK) Using a Novel Covalent Inhibitor PRN694. <i>Journal of Biological Chemistry</i> , 2015, 290, 5960-5978.	3.4	36
12	The Proteome-Wide Potential for Reversible Covalency at Cysteine. <i>Angewandte Chemie - International Edition</i> , 2019, 58, 11385-11389.	13.8	36
13	De Novo Fragment Design: A Medicinal Chemistry Approach to Fragment-Based Lead Generation. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 3115-3119.	6.4	30
14	Discovery of a Novel Series of Potent Non-Nucleoside Inhibitors of Hepatitis C Virus NS5B. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 8163-8182.	6.4	29
15	Discovery of N-[4-[6-tert-Butyl-5-methoxy-8-(6-methoxy-2-oxo-1H-pyridin-3-yl)-3-quinolyl]phenyl]methanesulfonamide (RG7109), a Potent Inhibitor of the Hepatitis C Virus NS5B Polymerase. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 1914-1931.	6.4	25
16	Discovery of Reversible Covalent Bruton's Tyrosine Kinase Inhibitors PRN473 and PRN1008 (Rilzabrutinib). <i>Journal of Medicinal Chemistry</i> , 2022, 65, 5300-5316.	6.4	24
17	Characterization of RO5126946, a Novel 7 Nicotinic Acetylcholine Receptor "Positive Allosteric Modulator. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 350, 455-468.	2.5	21
18	3-Heterocyclyl quinolone inhibitors of the HCV NS5B polymerase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 300-304.	2.2	18

#	ARTICLE	IF	CITATIONS
19	Conformational analysis of aqueous pullulan oligomers: an effective computational approach. <i>Polymer</i> , 2002, 43, 509-516.	3.8	15
20	The Proteomeâ€Wide Potential for Reversible Covalency at Cysteine. <i>Angewandte Chemie</i> , 2019, 131, 11507-11511.	2.0	7
21	A phase 1, multicenter, dose-escalation study of PRN1371, an irreversible covalent FGFR1-4 kinase inhibitor, in patients with advanced solid tumors, followed by expansion cohorts in patients with FGFR genetic alterations.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS2616-TPS2616.	1.6	1